Progress on CSL’s emissions targets In achieving CSL’s emission reduction targets, the Company does not anticipate seeing a linear reduction in the early years, especially in Scope 1 emissions, which are more difficult to reduce. Compared to FY2024, there was no significant movement in Scope 1 emissions in FY2025. CSL continues to execute its roadmap of deploying energy efficiency measures and reduction projects needed to meet its FY2030 commitment, while maintaining optimal operational capability to meet the levels of production needed to manufacture its products. In FY2025 the results and outcomes of the extensive projects and initiatives across the CSL network had begun to be realised, CSL’s Scope 2 emissions have decreased by approximately 29%, since FY2024. This was largely driven by CSL’s Australian sites’ move to renewable electricity from 1 January 2025 as part of its Renewable-Linked Power Purchase Agreement (PPA) with AGL. CSL has continued engaging with its suppliers that contribute to CSL’s Scope 3 emissions. To date, CSL has actively engaged with 71.3% of suppliers by emissions to set SBTi aligned targets and currently 54.2% of CSL’s suppliers by emissions^ have self‑reported to have Scope 1 and 2 SBTi aligned targets. ^ Based on the supplier’s proportion of CSL’s total FY2023 Scope 3 emissions. Healthier Environment Earth Day photo competition winner Mystical Lake Atitlán Image by: Jhanzelle Francis, Senior Clinical Scientist CSL’s Energy and Emissions Indicator Unit 24–251,2,3 (Jul–Jun) 23–241,2,3 (Jul–Jun) 22–231,2 (Apr–Mar) Scope 1 GHG emissions4 Metric kilotonnes CO2-e (KT) 135 133 113 Scope 2 GHG emissions4 Metric kilotonnes CO2-e (KT) 151 215 223 Total Scope 1 and 2 GHG emissions4 Metric kilotonnes CO2-e (KT) 286* 348** 336*** Energy consumption5 Petajoules (PJ) 4.42* 4.48** 4.21*** 1. Data reported is inclusive of: CSL Behring’s manufacturing facilities in Australia, Germany, Switzerland, the United States (US) including CSL’s saline manufacturing facility and (until its divestment on 16 October 2024) China. CSL Seqirus’ three manufacturing facilities in Australia, the United Kingdom and US. 2. CSL Plasma operations, including plasma centres across China, Germany, Hungary and the US, two major plasma logistics centres and CSL Plasma’s United States laboratory. Administrative and R&D operations co-located with CSL’s manufacturing facilities and the respective head offices for CSL Behring (King of Prussia, US), CSL Plasma (Boca Raton, US) and CSL Limited (Melbourne, Australia). Note that CSL divested manufacturing and plasma centres in China in October 2024. This includes CSL Vifor’s manufacturing facility in Switzerland following acquisition in August 2022. 3. Energy use figures are based on invoices for supplied energy. Emissions are calculated based on this information and recognised emission factors. Where invoice data is not available for a month, the energy use has been estimated based on previous results. CSL Plasma uses validated factors to calculate electrical power and gas consumption. Utility invoices were used to establish these factors and calculate natural gas and electricity consumption for all CSL Plasma centres. Utility invoices were also used for CSL Plasma Logistic centres and laboratories (United States). 4. Total emissions are expressed as carbon dioxide equivalents (CO2-e). Scope 2 emissions are reported on a market basis. 5. This includes Scope 1 and 2 energy sources. Scope 1 energy sources are fossil energy sources used onsite such as natural gas, diesel, petrol and heating oil. Scope 2 energy sources are electricity, steam supplied to site, district heating (hot water) and chilled water. * Limited assurance provided by Deloitte. ** CSL has moved to 30 June year end reporting for its environmental data commencing in FY2025. CSL’s 2024 comparative has also been changed to reflect a period ending 30 June, as such due to seasonality the FY2024 numbers will be different to those reported for 2023–2024 (April–March) period in last year’s Annual Report. Limited assurance was provided by Deloitte on those numbers reported in the FY2024 Annual Report for the reporting period of April 2023 to March 2024. *** Limited assurance provided by Ernst & Young. 36 Healthier World
RkJQdWJsaXNoZXIy MjE2NDg3